Corresponding Author: Carol M. Mangione, MD, MSPH, David Geffen School of Medicine, University of California, Los Angeles, 10940 Wilshire Blvd, Ste 700, Los Angeles, CA 90024 (chair@uspstf.net)
Accepted for Publication: July 13, 2022.
The US Preventive Services Task Force (USPSTF) members: Carol M. Mangione, MD, MSPH; Michael J. Barry, MD; Wanda K. Nicholson, MD, MPH, MBA; Michael Cabana, MD, MA, MPH; David Chelmow, MD; Tumaini Rucker Coker, MD, MBA; Esa M. Davis, MD, MPH; Katrina E. Donahue, MD, MPH; Carlos Roberto Jaén, MD, PhD, MS; Martha Kubik, PhD, RN; Li Li, MD, PhD, MPH; Gbenga Ogedegbe, MD, MPH; Lori Pbert, PhD; John M. Ruiz, PhD; James Stevermer, MD, MSPH; John B. Wong, MD.
Affiliations of The US Preventive Services Task Force (USPSTF) members: University of California, Los Angeles (Mangione); Harvard Medical School, Boston, Massachusetts (Barry); University of North Carolina at Chapel Hill (Nicholson); Albert Einstein College of Medicine, New York, New York (Cabana); Virginia Commonwealth University, Richmond (Chelmow); University of Washington, Seattle (Coker); University of Pittsburgh, Pittsburgh, Pennsylvania (Davis); University of North Carolina at Chapel Hill (Donahue); The University of Texas Health Science Center, San Antonio (Jaén); George Mason University, Fairfax, Virginia (Kubik); University of Virginia, Charlottesville (Li); New York University, New York, New York (Ogedegbe); University of Massachusetts Medical School, Worcester (Pbert); University of Arizona, Tucson (Ruiz); University of Missouri, Columbia (Stevermer); Tufts University School of Medicine, Boston, Massachusetts (Wong).
Author Contributions: Dr Mangione had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The USPSTF members contributed equally to the recommendation statement.
Conflict of Interest Disclosures: Authors followed the policy regarding conflicts of interest described at https://www.uspreventiveservicestaskforce.org/Page/Name/conflict-of-interest-disclosures. All members of the USPSTF receive travel reimbursement and an honorarium for participating in USPSTF meetings.
Funding/Support: The USPSTF is an independent, voluntary body. The US Congress mandates that the Agency for Healthcare Research and Quality (AHRQ) support the operations of the USPSTF.
Role of the Funder/Sponsor: AHRQ staff assisted in the following: development and review of the research plan, commission of the systematic evidence review from an Evidence-based Practice Center, coordination of expert review and public comment of the draft evidence report and draft recommendation statement, and the writing and preparation of the final recommendation statement and its submission for publication. AHRQ staff had no role in the approval of the final recommendation statement or the decision to submit for publication.
Disclaimer: Recommendations made by the USPSTF are independent of the US government. They should not be construed as an official position of AHRQ or the US Department of Health and Human Services.
Additional Contributions: We thank Howard Tracer, MD (AHRQ), who contributed to the writing of the manuscript, and Lisa Nicolella, MA (AHRQ), who assisted with coordination and editing.
Additional Information: The US Preventive Services Task Force (USPSTF) makes recommendations about the effectiveness of specific preventive care services for patients without obvious related signs or symptoms. It bases its recommendations on the evidence of both the benefits and harms of the service and an assessment of the balance. The USPSTF does not consider the costs of providing a service in this assessment. The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize decision-making to the specific patient or situation. Similarly, the USPSTF notes that policy and coverage decisions involve considerations in addition to the evidence of clinical benefits and harms. Published by JAMA®—Journal of the American Medical Association under arrangement with the Agency for Healthcare Research and Quality (AHRQ). ©2022 AMA and United States Government, as represented by the Secretary of the Department of Health and Human Services (HHS), by assignment from the members of the United States Preventive Services Task Force (USPSTF). All rights reserved.
2.Xu
J , Murphy
SL , Kockanek
KD , Arias
E . Mortality in the United States, 2018.
NCHS Data Brief. 2020;(355):1-8.
PubMedGoogle Scholar 3.Virani
SS , Alonso
A , Benjamin
EJ ,
et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2020 update: a report from the American Heart Association.
Circulation. 2020;141(9):e139-e596. doi:
10.1161/CIR.0000000000000757PubMedGoogle ScholarCrossref 4.Virani
SS , Alonso
A , Aparicio
HJ ,
et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2021 update: a report from the American Heart Association.
Circulation. 2021;143(8):e254-e743. doi:
10.1161/CIR.0000000000000950PubMedGoogle ScholarCrossref 6.Goff
DC
Jr , Lloyd-Jones
DM , Bennett
G ,
et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
J Am Coll Cardiol. 2014;63(25, pt B):2935-2959. doi:
10.1016/j.jacc.2013.11.005PubMedGoogle ScholarCrossref 7.DeFilippis
AP , Young
R , Carrubba
CJ ,
et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort.
Ann Intern Med. 2015;162(4):266-275. doi:
10.7326/M14-1281PubMedGoogle ScholarCrossref 10.Dalton
JE , Perzynski
AT , Zidar
DA ,
et al. Accuracy of cardiovascular risk prediction varies by neighborhood socioeconomic position: a retrospective cohort study.
Ann Intern Med. 2017;167(7):456-464. doi:
10.7326/M16-2543PubMedGoogle ScholarCrossref 12.US Preventive Services Task Force. Collaboration and shared decision-making between patients and clinicians in preventive health care decisions and US Preventive Services Task Force recommendations.
JAMA. 2022;327(12):1171-1176. doi:
10.1001/jama.2022.3267PubMedGoogle ScholarCrossref 13.Chou
R , Cantor
A , Dana
T ,
et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: A Systematic Review for the US Preventive Services Task Force. Evidence Synthesis No. 219. Agency for Healthcare Research and Quality; 2022. AHRQ publication 22-05291-EF-1.
14.Dorsch
MP , Lester
CA , Ding
Y , Joseph
M , Brook
RD . Effects of race on statin prescribing for primary prevention with high atherosclerotic cardiovascular disease risk in a large healthcare system.
J Am Heart Assoc. 2019;8(22):e014709. doi:
10.1161/JAHA.119.014709PubMedGoogle ScholarCrossref 15.Schroff
P , Gamboa
CM , Durant
RW , Oikeh
A , Richman
JS , Safford
MM . Vulnerabilities to health disparities and statin use in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study.
J Am Heart Assoc. 2017;6(9):e005449. doi:
10.1161/JAHA.116.005449PubMedGoogle ScholarCrossref 16.Gamboa
CM , Colantonio
LD , Brown
TM , Carson
AP , Safford
MM . Race-sex differences in statin use and low-density lipoprotein cholesterol control among people with diabetes mellitus in the Reasons for Geographic and Racial Differences in Stroke study.
J Am Heart Assoc. 2017;6(5):e004264. doi:
10.1161/JAHA.116.004264PubMedGoogle ScholarCrossref 18.Wall
HK , Ritchey
MD , Gillespie
C , Omura
JD , Jamal
A , George
MG . Vital Signs: prevalence of key cardiovascular disease risk factors for Million Hearts 2022—United States, 2011-2016.
MMWR Morb Mortal Wkly Rep. 2018;67(35):983-991. doi:
10.15585/mmwr.mm6735a4PubMedGoogle ScholarCrossref 27.US Preventive Services Task Force. Behavioral counseling interventions to promote a healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: US Preventive Services Task Force recommendation statement.
JAMA. 2020;324(20):2069-2075. doi:
10.1001/jama.2020.21749PubMedGoogle ScholarCrossref 28.US Preventive Services Task Force. Behavioral counseling to promote a healthful diet and physical activity for cardiovascular disease prevention in adults without cardiovascular risk factors: US Preventive Services Task Force recommendation statement.
JAMA. 2017;318(2):167-174. doi:
10.1001/jama.2017.7171PubMedGoogle ScholarCrossref 29.US Preventive Services Task Force. Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults: US Preventive Services Task Force recommendation statement.
JAMA. 2018;320(11):1163-1171. doi:
10.1001/jama.2018.13022PubMedGoogle ScholarCrossref 31.Chou
R , Cantor
A , Dana
T ,
et al. Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US Preventive Services Task Force.
JAMA. Published August 23, 2022. doi:
10.1001/jama.2022.12138Google Scholar 34.Han
BH , Sutin
D , Williamson
JD ,
et al; ALLHAT Collaborative Research Group. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: the ALLHAT-LLT randomized clinical trial.
JAMA Intern Med. 2017;177(7):955-965. doi:
10.1001/jamainternmed.2017.1442PubMedGoogle ScholarCrossref 35.ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
JAMA. 2002;288(23):2998-3007. doi:
10.1001/jama.288.23.2998PubMedGoogle ScholarCrossref 36.Macedo
AF , Taylor
FC , Casas
JP , Adler
A , Prieto-Merino
D , Ebrahim
S . Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis.
BMC Med. 2014;12(51):51. doi:
10.1186/1741-7015-12-51PubMedGoogle ScholarCrossref 39.Porath
A , Arbelle
JE , Fund
N , Cohen
A , Mosseri
M . Statin therapy: diabetes mellitus risk and cardiovascular benefit in primary prevention.
Isr Med Assoc J. 2018;20(8):480-485.
PubMedGoogle Scholar 42.Grundy
SM , Stone
NJ , Bailey
AL ,
et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Circulation. 2019;139:e1082–1143. doi:
10.1161/CIR.0000000000000625
PubMedGoogle ScholarCrossref 43.Arnett
DK , Blumenthal
RS , Albert
MA ,
et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Circulation. 2019;140(11):e596-e646. doi:
10.1161/CIR.0000000000000678PubMedGoogle ScholarCrossref